Author

Kevin R. Lynch

University of VirginiaORCID 0000-0002-7376-922XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alban GaultieriD· 1 shared Andrea R. MerchakiD· 1 shared Brant E. IsaksoniD· 1 shared Caitlin M. PaveleciD· 1 shared Daniel J. FosteriD· 1 shared George M. P. R. SouzaiD· 1 shared Jung‐Bum ShiniD· 1 shared Katherine E. Nimchuk· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Alban GaultierORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Assessing Spns2-dependent S1P Transport as a Prospective Therapeutic Target

Yugesh Kharel, Tao Huang, Kyle Dunnavant, Daniel J. Foster, George M. P. R. Souza, Katherine E. Nimchuk, Andrea R. Merchak, Caitlin M. Pavelec, Zuzanna J. Juśkiewicz, Simon S. Alexander, Alban Gaultier, Stephen B.G. Abbott, Jung‐Bum Shin, Brant E. Isakson, Wenhao Xu, , Kevin R. Lynch

This study evaluates a novel S1P transport blocker, SLF80821178, showing efficacy in multiple sclerosis without the cardiac side effects of SRMs, but with less lymphopenia and unchanged lymph S1P levels.

British Journal of Pharmacology · Feb 2, 2025Peer-reviewedPharmacology & Toxicology